CBD for kids has one properly evidenced medical use and a great deal of marketing around everything else. Randomised trials support purified, pharmaceutical grade cannabidiol as an add on treatment for three rare, drug resistant childhood epilepsy syndromes, prescribed and monitored by a specialist. Outside those conditions the trial evidence in children is thin, side effects are real, and retail products are frequently mislabelled. In South Africa this is a paediatrician led decision.
Last updated:
Key takeaways
- The evidence for CBD for kids is syndrome specific: Dravet, Lennox-Gastaut and tuberous sclerosis complex, all drug resistant epilepsies.
- For anxiety, sleep, autism or behaviour in children, high quality trial evidence is not there yet.
- Side effects are common: diarrhoea, sleepiness, sedation and raised liver enzymes.
- A JAMA analysis of 84 online CBD products found only 30,95 percent were accurately labelled, and THC turned up in 18 of them.
- In South Africa, anything at a therapeutic strength is prescription only, through a doctor.
What the evidence for CBD for kids actually supports
A 2023 systematic review and meta analysis in Experimental Neurology pooled six randomised controlled trials of highly purified oral cannabidiol in patients with Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex. All six were judged at low risk of bias.
Pooled, cannabidiol beat placebo on the odds of a meaningful seizure reduction, with an odds ratio of 2.45 and a 95 percent confidence interval of 1.81 to 3.32. Broken down by syndrome, the odds of at least a 50 percent reduction in seizures were 2.26 for Dravet syndrome, 2.98 for Lennox-Gastaut syndrome and 1.99 for tuberous sclerosis complex. The same analysis found cannabidiol was associated with more adverse events than placebo, with an odds ratio of 1.81.
The individual trials tell the same story. In the New England Journal of Medicine Dravet trial, median convulsive seizures per month fell from 12.4 to 5.9 on cannabidiol against 14.9 to 14.1 on placebo. In the Lennox-Gastaut trial, drop seizures fell by a median of 41.9 percent on the higher dose versus 17.2 percent on placebo.
Read that carefully, because it is the whole basis for taking CBD for kids seriously. Real benefit, in named severe syndromes, as an addition to existing antiseizure medicines, with more side effects than placebo. Not a cure, not a general wellness supplement, and not a replacement for anything.
| Use in children | Evidence position | Who decides |
|---|---|---|
| Dravet syndrome | Supported by randomised controlled trials as an add on therapy | Paediatric neurologist |
| Lennox-Gastaut syndrome | Supported by randomised controlled trials as an add on therapy | Paediatric neurologist |
| Tuberous sclerosis complex | Supported by randomised controlled trial evidence in the pooled analysis | Paediatric neurologist |
| Anxiety, sleep, behaviour, autism, ADHD | Small studies and anecdote only, no adequate paediatric trial base | Not established |
| General wellness or daily supplement | No trial evidence of benefit in healthy children | Not supported |
Where the evidence runs out
Most parents arriving at this question are not asking about Dravet syndrome. They are asking about a child who is anxious, who does not sleep, who is struggling at school, or who has an autism diagnosis. That is a completely different evidence picture.
For those uses there are small open label studies, parent surveys and a large volume of testimonial. What there is not is the kind of randomised, placebo controlled paediatric trial that separates a real drug effect from the natural ups and downs of childhood and from the strong placebo response that children and their parents both show. Absence of evidence is not proof of harm, but it does mean nobody can currently tell you the size of the benefit, the right dose, or the effect of long term use on a developing brain.
Before you start
Never give a cannabis based product to a child on your own initiative, and never reduce or stop a prescribed medicine in order to try one. In epilepsy in particular, withdrawing an antiseizure medicine can trigger breakthrough seizures.
In South Africa, cannabidiol at therapeutic strength and anything containing THC are prescription only, obtained through a registered doctor and dispensed by a pharmacy, sometimes via a SAHPRA Section 21 authorisation. This page is written for adults, parents and caregivers, and is general information rather than medical advice. Speak to a paediatrician, paediatric neurologist or pharmacist before starting, stopping or changing any treatment, and about dosing.
The product problem, and why a shop bought bottle is not the trial medicine
The trials used a purified, pharmaceutical grade cannabidiol solution of known strength and purity. A retail bottle is a different object, and the gap has been measured.
Researchers writing in JAMA in 2017 bought 84 cannabidiol products from 31 companies selling online and had them analysed by laboratory. Only 30,95 percent were accurately labelled. Nearly 43 percent contained more cannabidiol than the label claimed and just over 26 percent contained less. THC, which is intoxicating, was detected in 18 of the 84 samples, at up to 6,43 mg per millilitre, despite not being what the buyer thought they were purchasing.
For an adult experimenting on themselves, a mislabelled bottle is a poor deal. For a small child, where body weight is low and an unexpected THC exposure lands much harder, it is a genuine safety problem. This is the single strongest practical argument that anything given to a child should be a prescribed, regulated product rather than a retail purchase.
How CBD for kids is regulated in South Africa
South African rules are their own, and overseas coverage misleads more often than it helps. Three things set the boundaries.
Scheduling. Under the notice published in Government Gazette 43347 on 22 May 2020, cannabidiol sits in Schedule 4, making it prescription only, with two narrow exceptions falling to Schedule 0: complementary medicines with no more than 600 mg of CBD per sales pack and a maximum daily dose of 20 mg making only a low risk claim, and ingested processed products containing 0,0075 percent or less CBD. THC sits in Schedule 6. A Schedule 0 retail product is capped far below therapeutic strength and its permitted low risk claim is not a treatment claim, so it is not the same category of thing as a prescribed medicine for a seizure disorder.
Section 21. Where a cannabis based medicine is not registered in South Africa, the treating doctor may apply to the South African Health Products Regulatory Authority for authorisation to use it for a named patient under Section 21 of the Medicines and Related Substances Act 101 of 1965. The prescriber applies, not the parent, and each application is decided on its own facts.
The Cannabis for Private Purposes Act. Act 7 of 2024 governs private cultivation and possession by adults. It does not create a medical supply route, and it does not apply to children. Treating the private use law as permission to give a home grown or informally sourced product to a child misreads it completely.
Questions worth asking a paediatrician
- Does my child’s diagnosis resemble the conditions where cannabidiol has randomised trial evidence?
- Which conventional treatments have been tried, at what doses, and for how long?
- If cannabidiol were added, which current medicines would need blood level monitoring or a dose change?
- What baseline and follow up blood tests would be needed, including liver function?
- Would this be a registered medicine, or would it need a Section 21 application, and what does that process involve?
- What would count as success, measured how, and at what point would we stop?
- What are the known unknowns for a child of this age using this long term?
Related reading on this site: our guide to cannabis and epilepsy covers the seizure evidence in more depth, how to talk to your doctor about cannabis helps you prepare for the appointment, and medical cannabis dosage in South Africa explains why dosing belongs to a prescriber.
How Professor Green fits into the process
Professor Green is a South African medical cannabis platform for adults. Registering creates an account and opens the member area, which is where the store journey begins. Being precise matters more than usual on this topic, so here is what it is not.
Professor Green does not assess children, does not diagnose, does not prescribe and does not lodge Section 21 applications. Those acts belong to registered practitioners: a paediatrician or paediatric neurologist assesses and prescribes, a pharmacy dispenses, and SAHPRA decides a Section 21 application. Registration is restricted to adults, it is a first step into the platform rather than a guarantee of eligibility or supply, and nothing on this page is a route to obtaining a cannabis product for a child. If a child is the patient, the correct first move is a specialist appointment, not an online sign up.
Adults researching their own access can read our explainer on whether cannabis is legal in South Africa, or register for store access to explore the platform.
Frequently asked questions about CBD for kids
Is CBD for kids safe?
Only within a narrow, supervised context. Purified cannabidiol has randomised trial evidence in three rare drug resistant epilepsy syndromes, with specialist prescribing and blood monitoring. Outside that, paediatric safety data is limited, side effects such as diarrhoea, sleepiness and raised liver enzymes are common, and retail products are often mislabelled.
Can I buy CBD oil for my child at a pharmacy or health shop?
Retail products sold under the South African Schedule 0 exception are capped at a maximum daily dose of 20 mg and may only carry a low risk claim. They are not authorised as a treatment for a medical condition in a child, and they are not the pharmaceutical grade product used in the trials.
Will CBD make my child high?
Cannabidiol is not intoxicating at studied doses, but product contamination is the real risk. A JAMA laboratory analysis detected THC, which is intoxicating, in 18 of 84 online CBD products. That is why a regulated, prescribed product matters far more for a child than for an adult.
Does CBD help children with anxiety, sleep problems or autism?
There is no adequate randomised controlled trial evidence in children for these uses. Small studies and parent reports exist, but they cannot separate a genuine drug effect from placebo response or ordinary change over time. No responsible clinician can currently promise a benefit.
Can cannabidiol replace my child’s epilepsy medicine?
No. Every trial added cannabidiol to existing antiseizure medicines rather than replacing them. Reducing or stopping a prescribed antiseizure medicine without specialist supervision risks breakthrough seizures and status epilepticus.
What side effects should parents watch for?
The pooled trial data found more adverse events on cannabidiol than placebo, most commonly diarrhoea, somnolence and sedation. Raised liver enzymes also occurred, which is why liver function testing forms part of monitoring. Report anything new to the prescribing doctor rather than adjusting treatment yourself.
Can I register with Professor Green on my child’s behalf?
No. Registration is for adults. Professor Green does not assess, diagnose or prescribe for children, and no registration substitutes for a paediatric specialist. If a child is the patient, start with a paediatrician or paediatric neurologist.
The bottom line on CBD for kids
The honest answer on CBD for kids is narrower than either the marketing or the fear suggests. In three rare, severe, drug resistant epilepsy syndromes, purified cannabidiol added to existing treatment reduces seizures more than placebo, at the cost of more side effects and a need for monitoring. Beyond that, the paediatric evidence does not yet support the claims being made, and the retail product market has a measured labelling problem that matters most for the smallest patients. In South Africa the route is a paediatrician, a prescription, a pharmacy, and where the medicine is unregistered a SAHPRA Section 21 authorisation. Start with the appointment.
Sources and references
- Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis. Experimental Neurology, 2023
- Devinsky O et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine, 25 May 2017
- Devinsky O et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine, 17 May 2018
- Bonn-Miller MO et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA, 7 November 2017
- SAHPRA. Communication to industry, scheduling status of THC and CBD (General Notice 586, Government Gazette 43347, 22 May 2020)
- SAHPRA. Section 21 access to unregistered medicines
- Medicines and Related Substances Act 101 of 1965
- Cannabis for Private Purposes Act 7 of 2024, Government Gazette 50744, 3 June 2024
- An update on safety and side effects of cannabidiol, a review of clinical data and relevant animal studies
- Drug interactions of tetrahydrocannabinol and cannabidiol in cannabinoid drugs, recommendations for clinical practice
- Health Professions Council of South Africa, for confirming a practitioner is registered
For adults exploring legal access
Professor Green registration is for adults, and it opens the member area rather than promising supply or eligibility. If a child is the patient, the next step is a paediatrician, not a sign up form. Diagnosis, prescribing and dispensing always stay with your doctor and pharmacy.
Register for Store Access

